Abstracts tagged "anti-TNF therapy"

Abstract Number: 1732 • 2015 ACR/ARHP Annual Meeting
Slow Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Fiona Maas¹, Suzanne Arends¹, Ivette Essers², Elisabeth Brouwer¹, Eveline van der Veer³, Freke Wink⁴, Monique Efde⁴, Hendrika Bootsma¹ and Anneke Spoorenberg¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Assessing radiographic progression in ankylosing spondylitis (AS) is challenging. The results regarding the effect of tumor necrosis factor-alpha (TNF-α) blocking therapy on spinal radiographic…
Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 975 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Inhibition on Radiographic Progression in Ankylosing Spondylitis: An Observational Cohort Study of 374 Patients
Walter Maksymowych¹, Yufei Zheng², Stephanie Wichuk¹, Sasha Bernatsky³, Praveena Chiowchanwisawakit⁴ and Robert G Lambert⁵, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Alberta Institute of Health Economics, Edmonton, AB, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Radiology, Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: An analysis of radiographic progression in an observational cohort has suggested that anti-TNF therapy lessens radiographic progression, especially when treatment is introduced within 5…
Abstract Number: 1741 • 2015 ACR/ARHP Annual Meeting
Abdominal Fat Mass Assessment in Recent Onset Spondyloarthritis: Data from the DESIR Cohort
Hélène Che¹, Adrien Etcheto², Camille Souffir³, Sami Kolta⁴, Pascal Richette⁵, Anna Molto⁶, Maxime Dougados², Christian Roux⁴ and Karine Briot⁴, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Service de rhumatologie, Hopital Cochin, Paris, France, ⁴Rheumatology B Department, Hôpital Cochin, Paris, France, ⁵Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ⁶Hopital Cochin, Paris Descartes University, Paris, France
Background/Purpose: Studies have shown a strong prevalence of cardiovascular events among patients with spondyloarthritis (SpA). Recent studies indicate that visceral adipose tissue (VAT) is highly…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 2966 • 2014 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Marieke J.H. Coenen¹, Maša Umicevic-Mirkov¹, Sophine B. Krintel², Julia Johansen³, Corinne Miceli-Richard⁴, Henrik Kallberg⁵, Hans Scheffer¹, Wietske Kievit¹, Mart A. van de Laar⁶, Piet L.C.M. van Riel¹, X. Mariette⁷, Saedis Saevarsdottir⁸, Merete Lund Hetland⁹, Sita Vermeulen¹ and Cornelis A. Albers¹, ¹Radboud university medical center, Nijmegen, Netherlands, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Department of Medicine, Herlev, University of Copenhagen, Frederiksberg, Denmark, ⁴Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶University Twente & Medisch Spectrum Twente, Enschede, Netherlands, ⁷Paris-Sud University, Paris, France, ⁸Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁹DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Pain is the dominant and prevailing symptom of rheumatoid arthritis (RA). Tumor necrosis factor inihibitors (TNFi) have proven very successful in pain reduction. Interestingly,…
Abstract Number: 2096 • 2014 ACR/ARHP Annual Meeting
Assessment of RA Heterogeneity in Two Independent Cohorts of Patients
Joshua Joung, Yauheniya Cherkas and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose RA is known to be a heterogeneous disease, with heterogeneity existing in both clinical symptoms and responses to therapies. Molecular assessment of this heterogeneity…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 464 • 2014 ACR/ARHP Annual Meeting
Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
Boulos Haraoui¹, Vivian P. Bykerk², Ronald van Vollenhoven³, Marc de Longueville⁴, Kristel Luijtens⁵, Pauline Ralston⁶ and Arthur Kavanaugh⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Giant Professional Ltd, London, United Kingdom, ⁷University of California San Diego, La Jolla, CA
Background/Purpose Certolizumab pegol (CZP) is approved for adult patients (pts) with rheumatic diseases (RA, PsA and AS) at a maintenance dose of 200mg every 2…
Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 2092 • 2014 ACR/ARHP Annual Meeting
Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity
Yauheniya Cherkas, Sarah Lamberth, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose The use of objective biomarkers of clinical disease characteristics such as disease activity would be beneficial in informing patients, physicians and payers. Recently, a…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].